Press release
United States Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Set to Record US$ 28.45 billion by 2033., Growth Surge by - MASH Drug Development, NASH Diagnostics, NAFLD Burden, Fatty Liver Disease Management
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Size 2026
Ready to scale in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/metabolic-dysfunction-associated-steatohepatitis-mash-market?kb
United States: Recent Industry Developments
✅ March 2026: Madrigal Pharmaceuticals accelerated commercialization activities for Rezdiffra (resmetirom) to strengthen its leadership position in the growing MASH treatment market.
✅ February 2026: Pfizer Inc. advanced development of combination therapies targeting fibrosis and metabolic pathways for patients with metabolic dysfunction-associated steatohepatitis (MASH).
✅ January 2026: Viking Therapeutics expanded clinical research programs for dual GLP-1/GIP candidates aimed at improving liver fat reduction and metabolic outcomes in MASH patients.
✅ December 2025: Akero Therapeutics reported positive clinical progress for efruxifermin (EFX), supporting advancement of next-generation therapies for liver fibrosis and NASH/MASH treatment.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-market?kb
Growth Forecast Projected 2026:
The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Key Developments 2025-2026:
✅ February 2026: Several advanced pipeline therapies in the U.S. progressed into Phase 3 clinical trials, focusing on anti-fibrotic, metabolic, and multi-target treatment approaches for improving liver histology and slowing disease progression.
✅ January 2026: Madrigal Pharmaceuticals announced strategic expansion plans during JPM 2026, including acquisition rights to Pfizer's DGAT-2 inhibitor ervogastat and oral GLP-1 candidate MGL-2086 to strengthen its position in the emerging MASH therapeutics landscape.
✅ December 2025: The global MASH treatment market reached approximately US$ 2.6 billion, supported by strong annual growth driven by increasing metabolic disorders, unhealthy dietary patterns, and sedentary lifestyles.
How Our Market Research Process Works:
The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) ecosystem.
Recent Mergers & Acquisitions (M & A) 2025-2026:
• April 2026: Novo Nordisk expanded its MASH portfolio strategy following broader global regulatory momentum for Wegovy in MASH-related indications.
• February 2026: Madrigal Pharmaceuticals signed an exclusive global licensing agreement with Suzhou Ribo Life Science and Ribocure for six preclinical siRNA programs targeting MASH.
• January 2026: Madrigal Pharmaceuticals entered an exclusive global license agreement with Pfizer for ervogastat and additional early-stage MASH assets to strengthen its combination therapy pipeline.
• January 2026: Madrigal Pharmaceuticals expanded its MASH combination therapy strategy through the acquisition/licensing of Pfizer's DGAT-2 inhibitor ervogastat with a $50 million upfront deal structure.
Request Strategic Market Customization: https://datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-mash-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company strengthened research initiatives focused on metabolic liver diseases and next-generation therapies for MASH management.
✅ February 2026: Eisai Co., Ltd. expanded collaborations in liver disease biomarker research to improve early diagnosis and treatment monitoring for MASH patients.
✅ January 2026: Mitsubishi Tanabe Pharma advanced pipeline activities targeting fibrosis-related liver disorders and metabolic dysfunction-associated steatohepatitis therapies.
✅ December 2025: Sumitomo Pharma explored AI-driven drug discovery approaches to accelerate development of novel treatments for chronic liver diseases including MASH.
Major Focused Key Segmentations 2026:
By Stage: Stage F0, Stage F1, Stage F2, Stage F3, Stage F4
Regional Growth Analysis for Market:
• North America recorded approximately 17.50 million prevalent cases in 2024, with nearly 3.49 million diagnosed cases and around 1.82 million patients receiving treatment.
• Europe accounted for nearly 29.30 million prevalent cases in 2024, including about 5.49 million diagnosed patients, of which approximately 2.50 million underwent treatment.
• Asia-Pacific represented the highest disease burden with nearly 190.28 million prevalent cases in 2024, while diagnosed cases reached 21.44 million and treatment cases were estimated at 7.00 million.
• Latin America reported approximately 37.18 million prevalent cases in 2024, with nearly 2.76 million diagnosed patients and around 0.64 million receiving treatment.
• Middle East & Africa recorded nearly 76.13 million prevalent cases in 2024, including about 4.67 million diagnosed cases, while approximately 0.76 million patients were estimated to be under treatment.
We Provide Benefits of the Report:
Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.
Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.
Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.
Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.
Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.
Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.
Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.
Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.
Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.
Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-mash-market?kb
Diagnosis
The diagnosis of MASH involves a combination of non-invasive imaging techniques, laboratory evaluations, and confirmatory tissue analysis to assess liver inflammation, fibrosis, and disease progression.
• Liver Stiffness Tests: Non-invasive imaging methods such as transient elastography (FibroScan) and magnetic resonance elastography (MRE) are widely used to evaluate liver stiffness, elasticity, and fibrosis severity.
• Blood Tests: Common diagnostic blood assessments include liver function tests measuring ALT (alanine aminotransferase) and AST (aspartate aminotransferase) levels, along with fibrosis evaluation tools such as the AST-to-Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) score to estimate liver scarring. Lipid profile analysis is also commonly performed.
• Liver Biopsy: Liver biopsy remains the gold standard confirmatory procedure for MASH diagnosis, involving microscopic examination of liver tissue to detect inflammation, fibrosis, and scarring, although its use is limited due to its invasive nature.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Set to Record US$ 28.45 billion by 2033., Growth Surge by - MASH Drug Development, NASH Diagnostics, NAFLD Burden, Fatty Liver Disease Management here
News-ID: 4506570 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Alzheimer's Disease Therapeutics Market Set for Significant Growth to US$ 17.98 …
DataM Intelligence has released a new research report titled "Alzheimer's Disease Therapeutics Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in…
Portable Oxygen Concentrators Market to Reach USD 6.46 Billion by 2033 at 12.1% …
The global portable oxygen concentrators market reached USD 2.60 billion in 2025 and is expected to reach USD 6.46 billion by 2033, growing at a CAGR of 12.1% during the forecast period from 2026 to 2033. The market is witnessing rapid growth driven by the increasing prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea, along with the rising geriatric population worldwide. Growing…
Particle Therapy Market to Reach USD 2.58 Billion by 2033 at 7.9% CAGR; North Am …
The global particle therapy market reached USD 1.44 billion in 2025 and is expected to reach USD 2.58 billion by 2033, growing at a CAGR of 7.9% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing global burden of cancer, rising demand for precision oncology treatments, and growing adoption of advanced radiation therapy technologies. Particle therapy is an advanced form of…
Knee Replacement Market to Reach USD 16.72 Billion by 2033 at 4.8% CAGR; North A …
The global knee replacement market reached USD 11.37 billion in 2025 and is expected to reach USD 16.72 billion by 2033, growing at a CAGR of 4.8% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the rising prevalence of osteoarthritis, increasing geriatric population, and growing incidence of obesity and joint-related disorders worldwide. Increasing demand for minimally invasive orthopedic procedures, improved patient outcomes,…
More Releases for MASH
Key Trends Reshaping the Metabolic Dysfunction-Associated Steatohepatitis (MASH) …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size pertaining to treatments for metabolic dysfunction-associated steatohepatitis (MASH) has witnessed substantial expansion lately, projected to surge from its 2024 valuation of $2 billion euros to $2.59 billion euros by 2025, reflecting a…
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Pepper Mash Market Size Estimated to grow USD 0.517 Billion by 2032
Pepper Mash Market Overview
The pepper mash market is a dynamic segment of the global food industry, characterized by its rich flavor profiles and wide-ranging applications. Pepper mash, a key ingredient in the production of hot sauces, seasonings, and processed foods, has gained significant traction due to its ability to impart heat and complexity to various dishes. This blog delves into the market overview, competitive landscape, key drivers, segmentation, and regional…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
